Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
11256026
ABSTRACT:
Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed.
REFERENCES:
patent: 3551443 (1970-12-01), Duennenberger et al.
patent: 4025636 (1977-05-01), Dunwell et al.
patent: 4025637 (1977-05-01), Dunwell et al.
patent: RE29608 (1978-04-01), Evans et al.
patent: 4107169 (1978-08-01), Schrage
patent: 4416892 (1983-11-01), Dawson
patent: 5200420 (1993-04-01), Goldmann et al.
patent: 5254692 (1993-10-01), Goldmann et al.
patent: 5354759 (1994-10-01), Lippert et al.
patent: 5412099 (1995-05-01), Goldmann et al.
patent: 5441946 (1995-08-01), Pauls et al.
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5563128 (1996-10-01), Pauls et al.
patent: 5714496 (1998-02-01), Brown et al.
patent: 5837390 (1998-11-01), Kishii et al.
patent: 6107491 (2000-08-01), Eldin
patent: 6277853 (2001-08-01), Perez et al.
patent: 6420418 (2002-07-01), Hagmann et al.
patent: 6495568 (2002-12-01), Dack et al.
patent: 6544989 (2003-04-01), Mathews et al.
patent: 6589953 (2003-07-01), Perez et al.
patent: 6602619 (2003-08-01), Lin et al.
patent: 6623930 (2003-09-01), Kerwin et al.
patent: 6689887 (2004-02-01), Kerwin et al.
patent: 6693098 (2004-02-01), Cournoyer et al.
patent: 6794403 (2004-09-01), Malamas et al.
patent: 2001/0056100 (2001-12-01), Cournoyer et al.
patent: 2002/0049142 (2002-04-01), Mathews et al.
patent: 2002/0061891 (2002-05-01), Perez et al.
patent: 2002/0107258 (2002-08-01), Kerwin et al.
patent: 2003/0040525 (2003-02-01), Kerwin et al.
patent: 2003/0129448 (2003-07-01), Lin et al.
patent: 2003/0199562 (2003-10-01), Malamas et al.
patent: 2003/0220367 (2003-11-01), Cournoyer et al.
patent: 2003/0232877 (2003-12-01), Sikorski et al.
patent: 2004/0006056 (2004-01-01), Harris et al.
patent: 2004/0029933 (2004-02-01), Fabre
patent: 2004/0048858 (2004-03-01), Sikorski et al.
patent: 2004/0102435 (2004-05-01), Barlaam et al.
patent: 2004/0229894 (2004-11-01), Kerwin et al.
patent: 2005/0090472 (2005-04-01), Yoshida et al.
patent: 2005/0282780 (2005-12-01), Labaudiniere
patent: 602336 (1934-08-01), None
patent: 2314238 (1973-09-01), None
patent: 4208535 (1992-09-01), None
patent: 4304650 (1994-08-01), None
patent: 0479161 (1992-04-01), None
patent: 0611660 (1994-08-01), None
patent: 04-183754 (1992-06-01), None
patent: 05-17458 (1993-01-01), None
patent: 06-073050 (1994-03-01), None
patent: 06-073051 (1994-03-01), None
patent: 06-239849 (1994-08-01), None
patent: 06-336586 (1994-12-01), None
patent: 07-097379 (1995-04-01), None
patent: 09-227576 (1997-09-01), None
patent: 09-328678 (1997-12-01), None
patent: 09-165391 (1999-06-01), None
patent: 2000100569 (2000-04-01), None
patent: 2001055332 (2001-02-01), None
patent: 2001064166 (2001-03-01), None
patent: 2001064205 (2001-03-01), None
patent: 2001242165 (2001-09-01), None
patent: 2001291593 (2001-10-01), None
patent: 2001301329 (2001-10-01), None
patent: 2002003368 (2002-01-01), None
patent: 2004250411 (2004-09-01), None
patent: 2004302049 (2004-10-01), None
patent: WO98/27972 (1998-07-01), None
patent: WO00/78733 (2000-12-01), None
patent: WO01/12183 (2001-02-01), None
patent: WO01/14354 (2001-03-01), None
patent: WO01/27088 (2001-04-01), None
patent: WO01/74786 (2001-10-01), None
patent: WO02/016333 (2002-02-01), None
patent: WO02/46168 (2002-06-01), None
patent: WO02/051821 (2002-07-01), None
patent: WO03/020698 (2003-03-01), None
patent: WO03/045930 (2003-06-01), None
patent: WO04/046123 (2003-06-01), None
patent: WO03/074516 (2003-09-01), None
patent: WO03/089418 (2003-10-01), None
patent: WO04/064771 (2004-08-01), None
patent: WO04/083189 (2004-09-01), None
patent: WO04/083195 (2004-09-01), None
patent: WO04/084824 (2004-10-01), None
patent: WO04/092140 (2004-10-01), None
patent: WO04/094395 (2004-11-01), None
patent: WO04/098494 (2004-11-01), None
Denny et al., Mutation Research, 232 (1990) p. 233-241.
Hari et al., J. Org. Chem., 2001, vol. 66, pp. 991-996.
Robinson et al., “Lessons from the AN 1792 Alzheimer Vaccine: least we forget” Neurobiology of Aging, 25 (2004), pp. 609-615.
Denny et al., Mutation Research, Structure-Activity Relationship for the mutagenic activity of tricyclic intercalating agents inSalmonella typhimurium, 232(2) pp. 233-241 (1990).
Aydin et al., “Analgesic and Antispasmodic Activities of 2-(2-Nitro-phenyl)-1H-benzimidazole 5-Carboxylic Acid: Evidence for the Importance of the 2-(o-Substituted Phenyl) Group”,Pharmazie58:405-408 (2003).
Baures et al., “Discovering Transthyretion Amyloid Fibril Inhibitors by Limited Screening”,Bioorganic&Medicinal Chemistry6:1389-1401 (1998).
Baures et al., “Synthesis and Evaluation of Inhibitors of Transthyretin Amyloid Formation Based on the Non-Steroidal Anti-Inflammatory Drug, Flufenamic Acid”,Bioorganic&Medicinal Chemistry7:1339-1347 (1999).
Beaulieu et al., “Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery and Preliminary SAR of Benzimidazole Derivatives”,Bioorganic and Medicinal Chemistry Letters14:119-124 (2004).
Editorial, “Orphan Amyloid Diseases”,Nature Structural Biology7(4):259-260 (2000).
Essassi and Fifani, “Synthese et Heterocyclization des (Pyrazolyl-3(5))-2-Benzimidazoles en Catalyse par Transfert de Phase”,Bull Soc Chim Belg96(1):63-67 (1987) (abstract).
Göker and Tebrizli, “Synthesis of 1,2-Disubstituted Benzimidazole-9(6)-Carboxamides and Evaluation of Their Antimicrobial Activity”,II Farmaco51(1):53-58 (1996).
Göker et al., “Synthesis and Antimicrobial Activity of Some New 2-Phenyl-N-Substituted Carboxamido-1H-Benzimidazole Derivatives”,Arch Pharm Med Chem334::148-152 (2001).
Green et al., “Synthesis and Characterization of Potent Bivalent Amyloidosis Inhibitors That Bind Prior to Transthyretin Tetramerization”,J Am Chem Soc125:13404-13414 (2003).
Hammarström et al., “Trans-Suppression of Misfolding in an Amyloid Disease”,Science293:2459-2462 (2001).
Hammarström et al., “Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics”,Science299:713-716 (2003).
Haskell et al., “Neuraminidase Inhibition and Viral Chemotherapy”,Journal of Medicinal Chemistry13(4):697-704 (1970).
Hillard et al., Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems,Antimicrobial Agents and Chemotherapy43(7):1693-1699 (1999).
Hisano and Yabuta, “Synthesis of Organosulfur Compounds. VIII. Cyclization Products from the Modified Willgerodt-Kindler Reaction”,Chem Pharm Bull21(3):511-517 (1973).
Jennings et al., “Efficient Synthesis of (±)-seco-Cyclopropaneindoline Analogs of CC-1065”,Heterocyclic Communication7(1) (2001).
Kelly, “The Environment Dependency of Protein Folding Best Explains Prion and Amyloid Diseases”,PNAS95:930-932 (1998).
Klabunde et al., “Rational Design of Potent Human Transthyretin Amyloid Disease Inhibitors”,Nature Structural Biology7(4):31321 (2000).
Kim et al., “Structure-Activity Relationships of Benzimidazoles and Related Heterocycles as Topoisomerase I Poisons”,Bioorganic and Medicinal Chemistry4(4):621-630 (1996).
Kreimeyer et al., “Sumarin Analogues with a 2-Phenylbenzimidazole Moiety as Partial Structure”,Pharmazie52(4):268-271 (1997).
Lashuel, et al., “New Class of Inhibitors of Amyloid-beta Fibril Formation”,J. Biol. Chem.277(45):42881-42890 (2002).
Lee et al., “Solid-Phase Combinatorial Synthesis of Benzothiazole and 2,3-Dihydro-[1,5]-Benzothiazepine Derivatives”,Tetrahedron Letters42:109-111 (2001).
Lin et al., “Bioisosteric Replacement of Anilide with Benzoxazole:
Kelly Jeffery W.
Sekijima Yoshiki
Grazier Nyeemah
Jones Day
Saeed Kamal A.
The Scripps Research Institute
LandOfFree
Compositions and methods for stabilizing transthyretin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for stabilizing transthyretin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for stabilizing transthyretin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3733721